ReviewJournal of cellular and molecular medicine2009
Pharmacotherapeutic targets in Alzheimer's disease.
Review in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives.IBRO neuroscience reports · 2024Review
- Acid-base fractions separated from Streblus asper leaf ethanolic extract exhibited antibacterial, antioxidant, anti-acetylcholinesterase, and neuroprotective activities.BMC complementary and alternative medicine · 2018Article
- Chameleon sequences in neurodegenerative diseases.Biochemical and biophysical research communications · 2016Article
- Antioxidant and Anticholinesterase Potential of Six Thymus Species.Evidence-based complementary and alternative medicine : eCAM · 2015Article
- Acetylcholinesterase inhibitory, antioxidant and phytochemical properties of selected medicinal plants of the Lamiaceae family.Molecules (Basel, Switzerland) · 2014Article
- Characterization of the role of the antioxidant proteins metallothioneins 1 and 2 in an animal model of Alzheimer's disease.Cellular and molecular life sciences : CMLS · 2012Article
- Dementia resulting from traumatic brain injury: what is the pathology?Archives of neurology · 2012Review
- Metal chaperones: a holistic approach to the treatment of Alzheimer's disease.Frontiers in psychiatry · 2012Article
- Mechanism of copper(II)-induced misfolding of Parkinson's disease protein.Scientific reports · 2011Article
- Site-activated chelators derived from anti-Parkinson drug rasagiline as a potential safer and more effective approach to the treatment of Alzheimer's disease.Neurochemical research · 2010Article
- Selective acetylcholinesterase inhibitor activated by acetylcholinesterase releases an active chelator with neurorescuing and anti-amyloid activities.ACS chemical neuroscience · 2010Article
- Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.Archives of toxicology · 2010Review
- Astrocytes in Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2010Review
- Murine models of Alzheimer's disease and their use in developing immunotherapies.Biochimica et biophysica acta · 2010Review
- eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer's disease.PloS one · 2010Article
- Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.Brain structure & function · 2010Review
- Central nervous system delivery of large molecules: challenges and new frontiers for intrathecally administered therapeutics.Expert opinion on drug delivery · 2010Review
- Dementia resulting from traumatic brain injury.Dementia & neuropsychologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder which is characterized by an increasing impairment in normal memory and cognitive processes that significantly diminishes a person's daily functioning. Despite decades of research and advances in our understanding of disease aetiology and pathogenesis, there are still no effective disease-modifying drugs available for the treatment of AD. However, numerous compounds are currently undergoing pre-clinical and clinical evaluations. These candidate pharma-cotherapeutics are aimed at various aspects of the disease, such as the microtubule-associated tau-protein, the amyloid-beta(Abeta) peptide and metal ion dyshomeostasis--all of which are involved in the development and progression of AD. We will review the way these pharmacological strategies target the biochemical and clinical features of the disease and the investigational drugs for each category.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.